Finder makes money from featured partners, but editorial opinions are our own.

How to buy ResMed (RMD) shares in Australia

Learn how to easily invest in ResMed shares.

ResMed
AU: RMD - AUD
A$24.61
+ A$0.32 ( + 1.32%)
MEDICAL INSTRUMENTS & SUPPLIES

ResMed is a medical instruments & supplies business based in Australia. ResMed shares (RMD) are listed on the Australian Securities Exchange (ASX) and all prices are in Australian dollars. ResMed has a trailing 12-month revenue of around $4.4 billion. If you're looking to buy shares, check out the steps below.

How to buy shares in ResMed

  1. Compare share trading platforms. To buy shares listed in Australia, you'll need to sign up to a broker with access to the ASX. Our table can help you choose.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, such as your ID and tax file number. Fund your account with a bank transfer, PayPal or debit card.
  3. Search for ResMed. Find the share by name or ticker symbol: RMD. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until ResMed reaches your desired price. Look into dollar-cost averaging to spread out your risk, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At today's price, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs.
  6. Check on your investment. Congratulations, you own a part of ResMed. Optimise your portfolio by tracking how your stock and the business performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that affect your stock.

ResMed stock price (ASX:RMD)

Use our graph to track the performance of RMD stocks over time.

ResMed shares at a glance

Information last updated 2023-11-27.
52-week range$21.14 - $36.37
50-day moving average $22.7636
200-day moving average $29.1892
Target price$30.79
PE ratio 25.4
Dividend yield $1.8 (1.28%)
Earnings per share (TTM) $0.94

Compare share trading platforms

The value of your investments can fall as well as rise and you may get back less than you invested. Past performance is no indication of future results.
1 - 6 of 6
Name Product Standard brokerage fee Inactivity fee Asset class
eToro
Finder AwardExclusive
eToro
$0
US$10 per month if there’s been no log-in for 12 months
ASX shares, Global shares, US shares, ETFs
CFD service. Capital at risk.
Finder exclusive: Get 12 months of investment tracking app Delta PRO for free when you fund your eToro account (T&Cs apply).
Join the world’s biggest social trading network when you trade stocks, commodities and currencies from the one account.
IG Share Trading
Finder Award
IG Share Trading
$8
$0
ASX shares, Global shares, US shares, UK shares, ETFs
$0 brokerage for US and global shares plus get an active trader discount of $5 commission on Australian shares.
Enjoy some of the lowest brokerage fees on the market when trading Australian and international shares, plus get access to 24-hour customer support.
Moomoo Share Trading
$3
$0
ASX shares, Global shares, US shares, ETFs
Finder exclusive: Get an additional 30 days on top of the regular brokerage-free period for new accounts (see link for details). T&Cs apply.
Trade shares on the ASX, the US markets and buy ETFs with Moomoo. Plus join a community over 18 million investors.
CMC Invest
Finder Award
CMC Invest
$0
$0
ASX shares, Global shares, Options trading, US shares, mFunds, ETFs
$0 brokerage on global shares including US, UK and Japan markets.
Trade up to 35,000 products, including shares, crypto, ETFs and managed funds, with access to 15 major global and Australian stock exchanges. Plus, buy Aussie shares for $0 brokerage up to $1,000. (Limited to one buy order per stock per trading day).
Webull
$4.90
$0
ASX shares, Options trading, US shares, ETFs
Earn US$100 in cash vouchers when you fund your new account with US$2,000 until March 30, 2024. Plus, earn up to 5.3% p.a. interest on your US cash account (T&Cs apply).
Trade ASX and US stocks and US options, plus gain access to inbuilt news platforms and educational resources. You can also start trading for less with fractional shares.
Tiger Brokers
Exclusive
Tiger Brokers
$5.50
$0
ASX shares, Global shares, US shares, ETFs
Finder exclusive: Get 15 commission-free trades on US or ASX equities for the first 180 days and US$50 fractional shares when you deposit at least US$500. Plus, all new customers get 1 free trade per month for the first 12 months (T&Cs apply).
Get one brokerage-free trade per month for the first 12 months for US or ASX markets. T&Cs apply.
loading

Is it a good time to buy ResMed stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. However, this is not a recommendation. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

ResMed price performance over time

Historical closes compared with the last close of A$24.29

1 week (2023-11-27) 5.20%
1 month (2023-11-03) 4.92%
3 months (2023-09-05) -0.94%
6 months (2023-06-05) -26.95%
1 year (2022-12-05) -27.73%
2 years (2021-12-03) -32.70%
3 years (2020-12-04) -12.85%
5 years (2018-12-05) 59.59%

Is ResMed under- or over-valued?

Valuing ResMed stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of ResMed's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

ResMed's P/E ratio

ResMed's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 25x. In other words, ResMed shares trade at around 25x recent earnings.

That's relatively low compared to, say, the P/E ratio for the ASX over the 12 months to December 2019 (32.14). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

ResMed's PEG ratio

ResMed's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.7467. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into ResMed's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

ResMed's EBITDA

ResMed's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $1.3 billion (£0.0 million).

The EBITDA is a measure of a ResMed's overall financial performance and is widely used to measure stock profitability.

ResMed financials

Revenue TTM $4.4 billion
Operating margin TTM 26.22%
Gross profit TTM $2.4 billion
Return on assets TTM 12.22%
Return on equity TTM 23.6%
Profit margin 20.72%
Book value 28.897
Market capitalisation $34.5 billion

TTM: trailing 12 months

ResMed share dividends

31%

Dividend payout ratio: 31.19% of net profits

Recently ResMed has paid out, on average, around 31.19% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 1.28% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), ResMed shareholders could enjoy a 1.28% return on their shares, in the form of dividend payments. In ResMed's case, that would currently equate to about A$1.8 per share.

While ResMed's payout ratio might seem fairly standard, it's worth remembering that ResMed may be investing much of the rest of its net profits in future growth.

The latest dividend was paid out to all shareholders who bought their shares by 8 November 2023 (the "ex-dividend date").

Have ResMed's shares ever split?

ResMed's shares were split on a 2:1 basis on 12 August 2010. So if you had owned 1 share the day before the split, the next day you would own 2 shares. This wouldn't directly have changed the overall worth of your ResMed shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for ResMed shares which in turn could have impacted ResMed's share price.

ResMed share price volatility

Over the last 12 months, ResMed's shares have ranged in value from as little as $21.14 up to $36.37. A popular way to gauge a stock's volatility is its "beta".

RMD.AU volatility(beta: 0.52)Avg. volatility(beta: 1.00)LowHigh

Beta measures a share's volatility in relation to the market. The market (AU average) beta is 1, while ResMed's is 0.521. This would suggest that ResMed's shares are less volatile than average (for this exchange).

ResMed overview

ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. It operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; U-Sleep, a compliance monitoring solution that enables home medical equipment (HME) to streamline their sleep programs; connectivity module and propeller solutions; and Propeller portal. It offers out-of-hospital software solution, such as Brightree business management software and service solutions to providers of HME, pharmacy, home infusion, orthotics, and prosthetics services; MatrixCare care management and related ancillary solutions to senior living, skilled nursing, life plan communities, home health, home care, and hospice organizations, as well as related accountable care organizations; HEALTHCAREfirst that offers electronic health record, software, billing and coding services, and analytics for home health and hospice agencies; and MEDIFOX DAN's software solutions. The company markets its products to sleep clinics, home healthcare dealers, and hospitals through a network of distributors and direct sales force. The company was founded in 1989 and is headquartered in San Diego, California.

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading CFDs comes with a higher risk of losing money rapidly due to leverage. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More guides on Finder

Ask an Expert

You are about to post a question on finder.com.au:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com.au is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder only provides general advice and factual information, so consider your own circumstances, or seek advice before you decide to act on our content. By submitting a question, you're accepting our Terms of Use, Disclaimer & Privacy Policy and 6. Finder Group Privacy & Cookies Policy.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Go to site